pre-IPO PHARMA

COMPANY OVERVIEW

Integral Molecular is a research-driven biotechnology company creating innovative technologies and a pipeline of therapeutic antibodies for under-exploited membrane protein targets, including GPCRs, ion channels, and transporters. The Company has over a decade of experience in optimizing membrane proteins, enabling the isolation, characterization, and engineering of monoclonal antibodies against otherwise intractable membrane protein targets. Its customers include all of the top pharmaceutical and biotechnology companies.


LOCATION

  • Philadelphia, PA, USA

  • THERAPEUTIC AREAS

  • Immunology
  • Metabolic DIsorders
  • Oncology
  • Pain

  • WEBSITE

    https://www.integralmolecular.com


    CAREER WEBSITE

    https://www.integralmolecular.com/company/careers/


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Jun 21, 2023

    Integral Molecular Awarded $1 Million by Commonwealth of Pennsylvania to Support Biotechnology Pandemic Research Center


    May 23, 2023

    A Shot in the Arm for Flu Research: Integral Molecular Introduces Off-the-Shelf Reagents to Evaluate 2023/2024 Influenza Vaccine Efficacy


    Apr 21, 2023

    Integral Molecular Opens New Research Center in Philadelphia Encompassing Pandemic Preparedness Laboratories


    Jan 5, 2023

    Integral Molecular Reveals Mechanism Underlying Exquisite Specificity of Claudin 6 Therapeutic Antibody Being Developed for Solid Tumors


    Oct 20, 2022

    Integral Molecular Launches New Product Lines of Safe Reporter Viruses for Vaccine Development and Pandemic Preparedness


    For More Press Releases


    Google Analytics Alternative